Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects

Expert Opinion on Investigational Drugs

Volumn 10, Issue 8, 2001, Pages 1531-1544

  Borodic, G E ^a   Acquadro, M ^a   Johnson, E A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blepharospasm; Botulinum toxin; Dystonia; Facial pain; Inflammation; Meige syndrome; Migraine headache; Movement disease; Myofascial pain; Tension headache; Torticollis; Toxin formulation; Toxin quality; Trigeminal neuralgia

Indexed keywords

BOTULINUM TOXIN; PROTEIN; SNARE PROTEIN;

ADULT; ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; BIOTECHNOLOGY; BLEPHAROSPASM; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DIFFUSION; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG PURIFICATION; FACE PAIN; FEMALE; HUMAN; HYPOTHESIS; INFLAMMATION; INJECTION; INVOLUNTARY MOVEMENT; MEIGE DISEASE; MUSCLE DISEASE; NONHUMAN; PAIN; PHARMACOLOGY; PROTEIN STABILITY; REVIEW; TORTICOLLIS;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; BOTULINUM TOXINS; FACIAL PAIN; HUMANS; HYPERSENSITIVITY; INFLAMMATION; MEMBRANE PROTEINS; MIGRAINE DISORDERS; MOVEMENT DISORDERS; NEUROMUSCULAR DISEASES; PAIN; SNARE PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 0034895356     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.8.1531     Document Type: Review

References (92)

1. Treatment of myofascial pain with botulinum toxin
2. Botulinum A toxin for adult onset spasmodic torticollis
3. Neurotoxigenic clostridia
4. Clostridium botulinum neurotoxin
5. Structure and function of Clostridium botulinum progenitor toxin
6. Botulinum toxin: The story of its development for the treatment of human disease
7. Clostridial toxins as therapeutic agents: Benefits of nature's most toxic proteins
8. Neurotoxins affecting neuroexocytosis
9. Tetanus and botulinum neurotoxins: Turning bad guys into good by research
10. Compartmental specificity of cellular membrane fusion encoded in SNARE proteins
11. Mechanisms of synaptic vesicle exocytosis
12. 2+ and drives membrane fusion
13. Properties and use of botulinum toxin and other microbial neurotoxins in medicine
14. Preparation and properties of botulinum toxin type A for medical use
15. Botulinum toxin therapy, immunologic resistance, and problems with available materials
16. Botulinum A toxin for the treatment of spasmodic torticollis, dysphagia and Regional Toxin Spread
17. Histologic changes in muscle and clinciopathologic correlations after therapeutic botulinum toxin administration
18. Histologic assessment of dose related diffusion and muscle fiber response after therapeutic botulinum toxin injections
19. Botulinum toxin for spasmodic torticollis, multiple vs. single point injections per muscle
20. Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: Differences between fast and slow muscles
21. Botulinum B toxin as an alternative to botulinum A Toxin, a histologic study
22. Histologic features of human orbicularis oculi treated with botulinum A toxin
23. Measurement of botulinum toxin activity: Evaluation of the lethality assay
24. The median paralysis unit: A more pharmacologically relevant unit of biologic activity for botulinum toxin
25. Selective block on synaptic transmission in ciliary ganglion by type A botulinum toxin in rabbits
26. The pupillary effects of retrobulbar injection of botulinum toxin A (oculinum) in albino rats
27. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy
28. Botulinum toxin decreases salivation from canine submandibular glands
29. Botulinum toxin type A therapy for palmar and digital hyperhidrosis
30. Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission
31. Botulism
32. Persistence of botulinum neurotoxin action in spinal cord cells
33. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals
34. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle
35. Botulism
36. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
37. Botulinum toxin type B: An open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients
38. Development of resistance to botulinum toxin type A in patients with torticollis
39. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
40. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia
41. Myofascial pain and dysfunction
42. Comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm
43. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome
44. Botulinum toxin in the treatment of myofascial pain syndrome
45. Botulinum toxin: New treatment for temporomandibular disorders
46. Photophobia, an unrecognized component of essential blepharospasm and Meige Syndrome
47. Diminished regional cerebral blood flow response to vibration in patients with blepharospasm
48. SNARE proteins mediate lipid bilayer fusion
49. On the action of botulinum neurotoxins A and E at cholinergic terminals
50. Botulinum toxin type A as a migraine preventive treatment
51. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
52. The trigemino-vascular system and migraine
53. 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the ratdura mater after trigeminal stimulation
54. Neurogenic model of migraine
55. Neuroeffector functions of sensory fibres: Implications for headache mechanisms and drug actions
56. Clinical effects and mechanism of action of sumatriptan in migraine
57. Increased plasma histamine levels in migraine patients
58. Neurotrophins, nociceptors, and pain
59. Nerve growth factor and nociception
60. Mast cell interactions with the nervous system: Relationship to mechanisms of disease
61. Mast cells synthesize, store, and release nerve growth factor
62. Nitric oxide induces vascular permeability changes in the guinea pig conjunctiva
63. NOS inhibitor antagonism of PGE2-induced mechanical sensitization of cutaneous C-fiber nociceptors in the rat
64. Botulinum type a toxin as a prophylactic treatment of chronic tension type headache
65. Experience in utilization of botulinum toxin for the treatment of head and neck pain disorders
66. Release of mast-cell mediators and alterations in lung function in patients with cholinergic urticaria
67. Exercise-induced anaphylaxis: A distinct form of physical allergy
68. Substance P as a potent stimulator of sneeze responses in experimental allergic rhinitis of guinea pigs
69. The role of nitric oxide in experimental allergic conjunctivitis
70. Elevated levels of substance P in tears of patients with allergic conjunctivitis and vernal keratoconjunctivitis
71. Role of substance P in experimental allergic conjunctivitis in guinea pigs
72. Involvement of tachykinins in plasma extravasation induced by bradykinin and low pH medium in the guinea-pig conjunctiva
73. Calcitonin gene-related peptide, neurokinin A and substance P: Effects on nociception and neurogenic inflammation in human skin and temporal muscle
74. Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain
75. Interstitial myofibrositis: Hypothesis on mechanism
76. Substance P in the serum of patients with rheumatoid arthritis
77. Neuropeptides in synovium of patients with rheumatoid arthritis and osteoarthritis
78. Intraneuronal substance P contributes to the severity of experimental arthritis
79. Increase in substance P and CGRP, but not somatostatin content of innervating dorsal root ganglia in adjuvant monoarthritis in the rat
80. Neuropeptides in the skin of patients with atopic dermatitis
81. Unique mechanistic features of allergic rhinitis
82. Neurogenic inflammation and reflex sympathetic dystrophy (in vivo and in vitro assessment in an experimental model)
83. Role of tachykinins in asthma
84. Experimental model of allergic conjunctivitis to ragweed in guinea pig
85. Treatment of trigeminal neuralgia
86. Trigeminal nerve peripheral branch phenol/glycerol injections for tic douloureux
87. Long term outcome of percutaneous thermocoagulation for trigeminal neuralgia
88. The long term outcome of microvascular decompression for trigeminal neuralgia
89. Neuropathic pain: Aetiology, symptoms, mechanisms, and management
90. Transcriptional and post-translational plasticity and the generation of inflammatory pain